A deep dive into CDK4/6 inhibitors: Evaluating real world toxicities and treatment paradigms in the elderly population

Abstract

Background

Cyclin-dependent kinase 4/6 inhibitors have become part of the standard of care in the treatment of hormone receptor positive, Her2Neu negative metastatic breast cancer. There is concern regarding the efficacy and potential increased cyclin-dependent kinase 4/6 inhibitors toxicity in the geriatric population in the community compared to the clinical trial population.

Methods

We evaluated patients treated with cyclin-dependent kinase 4/6 inhibitors from 2015 to 2019 and stratified according to age ≥70 and <70 years. Complete blood count from the first two cycles was recorded. Rates of hematologic toxicities, dose interruptions and reductions, progression-free survival, and overall survival were compared between both groups. We sought to assess the hematologic toxicities between the age groups and the relationship between previous chemotherapy exposure, bone metastasis and starting cyclin-dependent kinase 4/6 inhibitors dose with progression-free survival and overall survival.

Results

A total of 202 patients were included, 73 were ≥70 years and 129 were <70 years of age. There was no association between age group and grade of neutropenia or thrombocytopenia. There was a profound association between progression-free survival and overall survival and starting dose, where patients with recommended starting dose had higher progression-free survival and overall survival than those with a reduced dose (p = 0.0003 and p = 0.04).

Conclusions

Our study showed similar progression-free survival and overall survival between age groups without significant differences in neutropenia or thrombocytopenia toxicity. Nevertheless, we found an association between starting dose and progression-free survival and overall survival that has not been previously reported. Given the good tolerability across age groups and the improvement in progression-free survival and overall survival, patients should be treated at the cyclin-dependent kinase 4/6 inhibitors recommended dose and monitored appropriately.

Keywords

CDK4/6 inhibitors metastatic breast cancer adverse events hematologic toxicities

Get full access to this article

View all access options for this article.

References

American Cancer Society. Cancer facts & figures 2021. Atlanta: American Cancer Society, 2021.

Tripathy

Bardia

Sellers

. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin Cancer Res 2017; 23: 3251–3262.

Portman

Alexandrou

Carson

, et al. Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocr Relat Cancer 2019; 26: R15–R30.

Lam

Liu

Lee

C-S

. A review of CDK4/6 inhibitors. US Pharm 2020; 45: 3–8.

Finn

Crown

Lang

, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2–negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16: 25–35.

Finn

Martin

Rugo

, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016; 375: 1925–1936.

Hortobagyi

Stemmer

Burris

, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016; 375: 1738–1748.

Sledge

Jr Toi

Neven

, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2–negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. JAMA Oncol 2020; 6: 116–124.

Le Saux

Falandry

Gan

, et al. Inclusion of elderly patients in oncology clinical trials. Ann Oncol 2016; 27: 1799–1804.

10.

Harris

Taylor

Thielke

, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–381.

11.

Harris

Taylor

Minor

, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019; 95: 103208.

12.

Singh

Howie

Bloomquist

, et al. Abstract GS5-06: a U.S. Food and drug administration pooled analysis of outcomes of older women with hormone-receptor positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine based therapy. In: General session abstracts. American Association for Cancer Research, 2018, GS5-06-GS5-06.

13.

Howie

Singh

Bloomquist

, et al. Outcomes of older women with hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer treated with a CDK4/6 inhibitor and an aromatase inhibitor: an FDA pooled analysis. J Clin Oncol 2019; 37: 3475–3483.

14.

Rugo

Turner

Finn

, et al. Palbociclib plus endocrine therapy in older women with HR+/ Her2neu negative advanced breast cancer: a pooled analysis of randomized paloma clinical studies. Eur J Cancer 2018; 101: 123–133.

15.

Rogatko

Schoeneck

Jonas

, et al. Translation of innovative designs into phase I trials. J Clin Oncol 2007; 25: 4982–4986.

16.

Le Tourneau

Lee

Siu

. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009; 101: 708–720.

17.

Yang

Sequist

Zhou

, et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-lung 3 and 6 trials. Ann Oncol 2016; 27: 2103–2110.

18.

Halmos

Tan

Soo

, et al. Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: results from a global real-world study (RealGiDo). Lung Cancer 2019; 127: 103–111.

19.

Miao

Seetharamu

Sullivan

, et al. Impact of tyrosine kinase inhibitor starting dose on outcomes in patients with non-small cell lung cancer. J Pharm Pract 2021; 34: 11–16.

20.

Satoh

Inoue

Kobayashi

, et al. Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol 2011; 6: 1413–1417.

21.

Bekaii-Saab

Ahn

, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol 2019; 20: 1070–1082.

22.

Reiss

Mamtani

, et al. Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study. J Clin Oncol 2017; 35: 3575–3581.

23.

Yamazaki

Iwasaki

Takasaki

, et al. Efficacy and tolerability of initial low-dose lenvatinib to treat differentiated thyroid cancer. Medicine (Baltimore) 2019; 98: e14774.

24.

Berdelou

Borget

Godbert

, et al. Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid 2018; 28: 72–78.

25.

Miyamoto

Azuma

Ishii

, et al. Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer: a multicenter phase 2 trial. JAMA Oncol 2020; 6: e201250.

26.

Rosell

Carcereny

Gervais

, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239–246.

27.

Kish

Ward

Garofalo

, et al. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Res 2018; 20: 37.